Medical Device and Healthcare Industry Trends — 2026-06-04

Top 5 Headlines Today

• Growth in Global Medical Device Regulatory Market: The regulatory affairs market is expected to expand to $15.94 billion by 2035, with the U.S. market, valued at $21.4 billion in 2025, leading the way.

• FDA Eases Regulations on Wearable and AI Medical Devices: The FDA has released new guidelines significantly relaxing oversight for low-risk AI Clinical Decision Support (CDS) software and wearable devices.

• Korean Medical Device Industry Posts 6th Consecutive Trade Surplus: Domestic medical device production reached 12.36 trillion won in 2025, an 8.1% increase year-on-year, driven primarily by dental implants and ultrasound equipment.

• Favorable Environment for KOSDAQ Medical Device Firms: The introduction of a KOSDAQ stratification system helps separate medical device companies like Classys from biopharmaceutical firms, sending a positive signal for the medical device sector.

• 50% Increase in Innovative Medical Device Designations: In 2025, the MFDS designated 45 products as innovative medical devices incorporating advanced technologies like AI and big data, a 50% increase from the previous year.

2 sources

globenewswire.com

globenewswire.com

ml.globenewswire.com

ml.globenewswire.com

Key Corporate Trends

Classys — Expanding Globally Through Brazilian Distributor Acquisition

• What Happened: Recorded Q1 revenue of 87.2 billion won (up 13% year-on-year) and achieved an operating margin of 42.7% following the acquisition of the Brazilian distributor MedSystems.
• Key Figures: Quarterly revenue of 87.2 billion won; 42.7% operating margin; net profit decreased by 4.1% due to one-time accounting factors.
• Implications: Accelerating global expansion by strengthening distribution networks in the Americas. The superiority of the medical device sector under the new KOSDAQ stratification system may increase investment capacity.

MFDS · Policy · Regulation

Strengthening Periodic GMP Audit Standards

• Details: The grace period for sales suspension for In Vitro Diagnostic (IVD) medical devices that meet the Manufacturing and Quality Management Standards (MFDS notification) has been abolished ahead of the GMP expiration date.
• Target: IVD manufacturers and importers.
• Effective Date: After March 26, 2026.
• Industry Impact: Stricter quality control standards are expected to restrict imports and sales, increasing compliance costs for manufacturers. Domestic firms must proactively address quality standards for export products.

Digital Health · AI Medicine

Specific new news regarding digital health and AI within the Korean medical device and healthcare industry in the last 24 hours is limited. However, in a global context, the FDA’s AI regulatory easing guidelines are expected to positively influence the U.S. market entry strategies for Korean AI medical device companies (e.g., Lunit, VUNO).

Global MedTech Context

• FDA Eases Wearable/AI CDS Regulations: New FDA guidelines easing oversight on low-risk AI CDS software and wearable devices are expected to lower entry barriers for Korean wearable manufacturers (e.g., Samsung Electronics' Galaxy Watch).

• FDA Eases Regulations on General Wellness Devices: In early 2026, the FDA relaxed oversight standards for general wellness devices to promote the adoption of AI-based digital health products, expanding opportunities for Korean firms to develop and export wellness devices.

• Growth in Medical Device Regulatory Market: As the global medical device regulatory market grows, demand for regulatory consulting and approval support services from Korean firms is expected to increase.

Investment · M&A · IPO Trends

• Introduction of KOSDAQ Stratification System: The Korea Exchange has divided KOSDAQ into "Premium" and "Standard" tiers, improving the listing environment for the medical device sector by applying differentiated regulatory and disclosure standards for medical device firms versus biopharmaceutical companies.

Today's Insight

The FDA’s easing of AI and wearable regulations offers a significant opportunity for innovative Korean medical device companies. Combined with the 50% increase in MFDS innovative medical device designations in 2025, these global trends could further boost the export competitiveness of the Korean industry. Global M&A cases, such as the acquisition by Classys in Brazil, signal that overseas expansion strategies for medical device firms are becoming more concrete. However, improvements in reimbursement policies for domestic digital health services and the removal of regulatory barriers remain prerequisites for substantial growth.

Weekly Checkpoints

• Detailed analysis and industry interpretation of the new FDA AI medical device regulatory guidelines.
• Status of MFDS innovative medical device designations and announcement of the 2nd round of designations.
• Tracking changes in stock prices and funding opportunities for KOSDAQ-listed medical device firms.

Action Items for Readers

• Regulatory Managers: Download the latest AI medical device guidelines from the FDA and MFDS and re-evaluate product classifications.
• Investors: Check the global expansion strategies and earnings announcement schedules for KOSDAQ medical device companies (e.g., Classys).
• Manufacturers: Verify the application deadlines for innovative medical device designations in the first half of 2026 and review plans for integrating AI/big data technologies.